Zhang Jing, Li Xiang, Huang Leaf
Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi 330004, China.
Division of Molecular Pharmaceutics and Center of Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
J Control Release. 2014 Sep 28;190:440-50. doi: 10.1016/j.jconrel.2014.05.037. Epub 2014 May 27.
Breast cancer is the most frequently diagnosed malignancy in American women. While significant progress has been made in the development of modern diagnostic tools and surgical treatments, only marginal improvements have been achieved with relapsed metastatic breast cancer. Small interfering RNAs (siRNAs) mediate gene silencing of a target protein by disrupting messenger RNAs in an efficient and sequence-specific manner. One application of this technology is the knockdown of genes responsible for tumorigenesis, including those driving oncogenesis, survival, proliferation and death of cells, angiogenesis, invasion and metastasis, and resistance to treatment. Non-viral nanocarriers have attracted attention based on their potential for targeted delivery of siRNA and efficient gene silencing without toxicity. Here, we review promising, non-viral delivery strategies employing liposomes, nanoparticles and inorganic materials in breast cancer.
乳腺癌是美国女性中最常被诊断出的恶性肿瘤。尽管在现代诊断工具和手术治疗的发展方面取得了重大进展,但复发性转移性乳腺癌仅取得了微小的改善。小干扰RNA(siRNA)通过以高效且序列特异性的方式破坏信使RNA来介导靶蛋白的基因沉默。这项技术的一个应用是敲低负责肿瘤发生的基因,包括那些驱动肿瘤发生、细胞存活、增殖和死亡、血管生成、侵袭和转移以及耐药性的基因。非病毒纳米载体因其具有靶向递送siRNA和高效基因沉默且无毒性的潜力而受到关注。在此,我们综述了在乳腺癌中采用脂质体、纳米颗粒和无机材料的有前景的非病毒递送策略。